cas 38953-42-3|| where to buy 4-Amino-6-chloro-5-hydroxypyrimidine

Product Name:4-Amino-6-chloro-5-hydroxypyrimidine

IUPAC Name:4-amino-6-chloropyrimidin-5-ol

Packing Unit	Available Stock	Price($)
CM116619-100mg	in stock	Ȏŉ
CM116619-250mg	in stock	ưƄ
CM116619-1g	in stock	ǵŢĽ
CM116619-5g	in stock	ȎŢư

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 38953-42-3 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:38953-42-3; Molecular Formula:C4H4ClN3O; Melting Point:-; Smiles Code:OC1=C(Cl)N=CN=C1N; Density:

: Catalog Number:CM116619; Molecular Weight:145.55; Boiling Point:312.5°C at 760 mmHg; MDL No:MFCD13689013; Storage:Store at room temperature

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Remibrutinib; Novartis announced new positive data from the Phase III REMIX-1 and REMIX-2 studies investigating remibrutinib - a highly selective, oral Bruton's tyrosine kinase (BTK) inhibitor - in people with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. In the studies, remibrutinib met all primary and secondary endpoints at Week 12. Remibrutinib is a potential 'best-in-class' BTK inhibitor. It can covalently bind to the BTK enzyme of B cells and myeloid cells. While strongly inhibiting BTK activity, it reduces the systemic exposure of the drug and reduces the risk of adverse events and drug interactions.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.